(PYPD) PolyPid Ltd. Porters Five Forces Research

PolyPid Ltd.'s supplier power is higher when niche inputs have no true backup source. In biopharma, dual sourcing is often planned but hard to fully qualify, so incumbent vendors can press on price and lead times. That risk matters most during pivotal trials and launch prep, when any delay can slow regulatory and commercial plans.

• Few qualified alternatives raise vendor leverage.
• Lead-time risk is highest before launch.
• Trial supply gaps can delay milestones.

PolyPid Ltd. faces high supplier power because analytical labs, sterilization vendors, and logistics partners are often few in number and highly specialized. In clinical-stage work, a missed batch release or weak regulatory file can push trial timelines back and raise costs fast. Supplier bottlenecks can matter even more when capacity is tight and documentation quality is a gatekeeper.

• Specialized vendors are hard to replace.
• Capacity limits can delay trials.
• Bad documentation can block release.
• Delays hit clinical-stage cash burn hard.

Surgeons strongly shape adoption at PolyPid Ltd. because they choose what goes into the OR, but hospitals still control the budget and can wait for proof. One clean message: clinical buy-in is not the same as purchase power.

That makes customer power high when buyers ask for Phase III and real-world evidence before scaling use. If clinicians split on value, hospitals can delay uptake, compare alternatives, and push harder on price.

• Surgeons drive use, not budget.
• Hospitals want Phase III proof.
• Real-world data speeds wider adoption.
• Clinician split raises buyer power.

Buyers have strong fallback options because standard antibiotic prophylaxis and established infection-prevention bundles are already built into routine care. In 2025/2026, that means PolyPid Ltd. must compete against familiar, widely used, and usually low-cost protocols, which keeps pricing power tight.

• Standard care is easy to adopt.
• Existing bundles lower switching costs.
• Low-cost alternatives cap pricing.

The easier it is to stay with existing protocols, the more customer bargaining power rises.

Regulatory milestones and label scope can decide who locks in first-mover advantage. If another Company reaches approval first, it can build hospital habits and contract ties before PolyPid Ltd., raising PolyPid Ltd.’s market-access and education spend.

• First approval shapes buying habits

• Broader labels widen contract reach

• Late entry means higher launch spend

In this race, even a few quarters’ delay can shift revenue and pricing power to the early mover.

Medical evidence is the main battleground, because rivals win with head-to-head trials, meta-analyses, and real-world outcomes, not just product features. In surgical site infection care, the 2%-5% infection rate after surgery makes even small proof gaps matter for adoption and hospital budgets. Stronger publication records and guideline inclusion can push pricing pressure higher on PolyPid Ltd.

• Head-to-head data drives share
• Guidelines shape hospital uptake
• Better evidence weakens pricing

Antimicrobial coatings, impregnated dressings, and local-release materials can meet the same infection-prevention goal as D-PLEX100, so they act as partial substitutes in surgeon and hospital buying choices. Surgical site infections affect about 2% to 5% of operations, with treatment costs often running into thousands of dollars per case, so buyers compare protection, price, and ease of use. That keeps substitute pressure real.

• Partial, not direct, substitutes
• Compete on infection prevention
• Buying choice depends on cost and workflow

Process and protocol improvements are a real substitute for PolyPid Ltd.’s therapy because better surgical technique, faster procedures, and enhanced recovery pathways can lower infection risk without adding a new drug cost. In many hospitals, ERAS can cut length of stay by 1 to 3 days, so the economic case for a new infection-prevention therapy weakens when these protocols work well.

• Shorter procedures reduce exposure time.
• ERAS can trim 1-3 hospital days.
• Lower-cost protocols weaken pricing power.

As these protocols become more effective, the substitution threat rises because hospitals may prefer process fixes that fit existing budgets and workflows.

Clinical credibility is a real entry barrier in surgery. Buyers usually want randomized, peer-reviewed proof from trusted investigators, and clinical adoption can stall if that proof is thin. With surgical site infections still affecting about 2% to 5% of procedures, a new entrant must build evidence and physician trust from zero.

• Trusted studies drive surgeon adoption.

• Evidence build-out starts from scratch.

• Weak publication support slows uptake.

PolyPid Ltd. faces a low threat from new entrants because sterile, reproducible manufacturing for a specialty therapeutic is hard to build and validate. New players must prove consistent quality, stability, and supply reliability before hospitals will sign contracts, and that takes time, capital, and process control.

This scale gap matters in sterile pharma, where one failed batch or supply break can block adoption and raise switching risk for buyers. So the operational bar stays high and fast entry stays limited.

• Sterile output must stay consistent
• Hospital buyers demand supply reliability
• Validation and quality take time